Hosted on MSN1mon
Medigene and EpimAb to develop T cell engagers for solid tumoursMedigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell engagers (TCR-TCEs), the “off-the-shelf” immunotherapies for solid tumours.
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor ...
The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...
IRW-PRESS: Medigene AG: Medigene reicht Patent für neuartiges NK-spezifisches TCR-Konstrukt beim Europäischen Patentamt ein ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer ...
EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback